Cantor Fitzgerald Upgrades Endo Health (ENDP) to Hold

Cantor Fitzgerald upgraded Endo Health (NASDAQ: ENDP) from Sell to Hold.

Analyst Irina Rivkind Koffler said, "Though we take a conservative view of Auxilium's portfolio, we believe that Endo can attain +6.7% EPS accretion in 2015, with longer-term increases in EBITDA to facilitate additional M&A. We are not expecting meaningful deal flow over the next six months while Endo pays down a large portion of its mesh litigation settlement and works to integrate Auxilium. We believe that the worst is over and there is more visibility into longer -erm growth. Our prior SELL rating was predicated on valuation, not catalysts. For these reasons, we upgrade ENDP to HOLD from SELL while maintaining our $56 PT."

For an analyst ratings summary and ratings history on Endo Health click here. For more ratings news on Endo Health click here.

Shares of Endo Health closed at $64.04 yesterday.

You May Also Be Interested In

• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities
• Amazon.com (AMZN) PT Raised to $215 at UBS